Neurocrine Biosciences
NBIX
#1457
Rank
โ‚ฌ11.29 B
Marketcap
111,53ย โ‚ฌ
Share price
-4.42%
Change (1 day)
11.29%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2024 : โ‚ฌ0.23 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is โ‚ฌ0.23 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚ฌ0.38 B58.12%
2022-12-31โ‚ฌ0.24 B-36.97%
2021-12-31โ‚ฌ0.38 B16.01%
2020-12-31โ‚ฌ0.33 B-24.22%
2019-12-31โ‚ฌ0.44 B30.25%
2018-12-31โ‚ฌ0.33 B10.24%
2017-12-31โ‚ฌ0.30 B
2009-12-31โ‚ฌ8.04 M-26.93%
2008-12-31โ‚ฌ11.01 M982.17%
2007-12-31โ‚ฌ1.01 M-97.5%
2006-12-31โ‚ฌ40.65 M-18.93%
2005-12-31โ‚ฌ50.14 M2.87%
2004-12-31โ‚ฌ48.74 M68.45%
2003-12-31โ‚ฌ28.93 M281.23%
2002-12-31โ‚ฌ7.59 M17.88%
2001-12-31โ‚ฌ6.43 M56.75%
2000-12-31โ‚ฌ4.1 M33.35%
1999-12-31โ‚ฌ3.08 M21.86%
1998-12-31โ‚ฌ2.52 M87.5%
1997-12-31โ‚ฌ1.34 M0%
1996-12-31โ‚ฌ1.34 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚ฌ0.70 B 195.49%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ7.22 B 2,926.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ0.56 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ29.55 B 12,278.56%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ67.50 B 28,173.27%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ63.26 B 26,398.41%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.27 B 13.46%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ17.64 M-92.61%๐Ÿ‡บ๐Ÿ‡ธ USA